Skip to content
Peptide research

Cortistatin

Also known as Cortistatin-14 · CST-14
Category
Brain & Cognition
Administration routes
Injectable
Regulatory status
Not FDA-approved

A neuropeptide related to somatostatin, explored for sleep, anti-inflammatory, and pain effects. The case rests almost entirely on animal and mechanism studies; human evidence is minimal to absent, so benefits remain speculative. It shares somatostatin's growth-hormone suppression, may cause GI effects, and has essentially no human safety data. Not an approved drug in the US, and supply is unregulated research-grade product of uncertain purity.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Cortistatin (CST) is an endogenous neuropeptide closely related to somatostatin, named for its predominantly cortical expression and its ability to depress cortical activity. Discovered in 1996 by Luis de Lecea and colleagues, cortistatin exists primarily as cortistatin-14 (in rodents) and cortistatin-17 (in humans). Despite sharing 11 of 14 amino acids with somatostatin-14, cortistatin is encoded by a separate gene (CORT) on a different chromosome and has distinct physiological functions that go well beyond those of somatostatin.

Cortistatin binds all five somatostatin receptors (sst1-5) with similar affinity to somatostatin but also uniquely binds the ghrelin receptor (GHS-R1a) and the MrgX2 receptor, giving it a broader signaling repertoire. Its distinctive functions include enhancement of slow-wave sleep, depression of neuronal firing in the cortex and hippocampus, potent anti-inflammatory and immunomodulatory activity, and regulation of vascular smooth muscle cell proliferation. Unlike somatostatin, cortistatin is primarily expressed in cortical and hippocampal GABAergic interneurons rather than throughout the entire neuroendocrine axis.

Research has revealed that cortistatin plays important roles in neuroinflammation, cardiovascular protection, and neuroendocrine regulation. It acts as a natural anti-inflammatory agent by inhibiting macrophage activation, reducing pro-inflammatory cytokine production, and modulating T-helper cell balance. Cortistatin-deficient mice develop exaggerated inflammatory responses and accelerated atherosclerotic lesions, highlighting its role as an endogenous brake on inflammation and vascular disease.

How it works in the body

A neuropeptide that binds all five somatostatin receptors plus the ghrelin receptor (GHS-R1a) and MRGPRX2, a receptor also activated by other peptide ligands. Unlike somatostatin, it promotes slow-wave sleep through cortical neuron inhibition, has potent anti-inflammatory effects via macrophage deactivation, and modulates pain perception.

Research overview

Cortistatin research has grown significantly since its discovery in 1996, with particular focus on its unique functions that distinguish it from somatostatin. Key research areas include sleep, inflammation, cardiovascular protection, neuroendocrine regulation and pain. Sleep regulation — cortistatin enhances slow-wave sleep when administered intracerebroventricularly, an effect not shared by somatostatin, suggesting it acts through non-somatostatin receptors (de Lecea et al., Nature 1996). Anti-inflammatory effects — cortistatin potently suppresses macrophage and Th1 cell activation, reduces production of TNF-alpha, IL-6, and IL-12, and protects against experimental colitis, arthritis, and sepsis (Gonzalez-Rey et al., Ann NY Acad Sci 2008). Cardiovascular protection — cortistatin inhibits proliferation and migration of human vascular smooth muscle cells via sst2/sst5 and ghrelin receptor signaling, reducing neointimal hyperplasia in carotid ligation models (Duran-Prado et al., Circ Res 2013). Cortistatin-deficient mice develop worse neointimal lesions. Neuroendocrine regulation — cortistatin mimics somatostatin in suppressing GH secretion but shows unique dose-dependent biphasic effects on somatotropes (Luque et al., J Mol Endocrinol 2006). Pain modulation — cortistatin reduced pain behavior in rodent models through somatostatin receptors, mainly sstr2, with a contribution from ghrelin-receptor signaling. Approximately 300-400 publications exist in PubMed, with research primarily preclinical.

Who researches Cortistatin?

Commonly researched by

  • People researching cognitive enhancement

    Studied for neuroprotective effects, memory, or cognitive performance.

  • People exploring sleep quality improvement

    Researched for effects on sleep architecture, circadian rhythm, or sleep quality.

  • People researching inflammation management

    Studied for anti-inflammatory effects across various conditions.

  • People exploring pain management options

    Researched for analgesic or pain-modulating properties.

Important considerations for

  • Those with Diabetes or hypoglycemia risk

    Moderate

    Like somatostatin, cortistatin inhibits insulin and glucagon secretion. Can disrupt glucose homeostasis.

  • Those with Growth hormone deficiency

    Moderate

    Cortistatin suppresses GH secretion similarly to somatostatin. May worsen GH deficiency.

  • Those who are pregnant or breastfeeding

    Absolute

    No human safety data. Pleiotropic effects on multiple receptor systems make risk unpredictable.

Safety & interactions

Do not use if

  • Diabetes or hypoglycemia risk

    Moderate

    Like somatostatin, cortistatin inhibits insulin and glucagon secretion. Can disrupt glucose homeostasis.

  • Growth hormone deficiency

    Moderate

    Cortistatin suppresses GH secretion similarly to somatostatin. May worsen GH deficiency.

General cautions

  • Pregnancy

    Absolute

    No human safety data. Pleiotropic effects on multiple receptor systems make risk unpredictable.

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(3)

Rated by level of concern

  • Suppression of growth hormone secretion (shared with somatostatin)

    Moderate

    https://pubmed.ncbi.nlm.nih.gov/16595604/

  • Potential gastrointestinal effects from somatostatin receptor activation

    Moderate

    Class effect of somatostatin analogs (FDA labels for octreotide/lanreotide/pasireotide); cortistatin receptor binding per https://pubmed.ncbi.nlm.nih.gov/18374474/

  • Minimal human safety data available

    High

    https://pubmed.ncbi.nlm.nih.gov/35283140/ ; https://pubmed.ncbi.nlm.nih.gov/34789874/

Interaction summary(8)

Rated by direction with this peptide

  • Somatostatin analogs (octreotide, lanreotide, pasireotide)

    CautionModerate

    Cortistatin binds all five cloned somatostatin receptors and shares somatostatin's pharmacology, so co-administration is pharmacologically additive and would be expected to compound GH/IGF-1 suppression, glycemic disturbance, diarrhea and gallbladder toxicity. Extrapolated from receptor overlap plus analog class labeling; no co-administration study exists.

    Receptor overlap: https://pubmed.ncbi.nlm.nih.gov/18374474/ ; class adverse-effect profile from FDA labeling for octreotide/lanreotide/pasireotide

  • Growth hormone secretagogues and GH/GHRH analogs (ipamorelin, MK-677/ibutamoren, CJC-1295, tesamorelin, sermorelin)

    CautionModerate

    Directly antagonistic — cortistatin-17 blunted the GH response to GHRH and to a ghrelin analog by 30-50% in human pituitary adenoma cells, so using it with GH-secretagogue peptides would be expected to blunt their intended effect. Human ex vivo tissue data, not in vivo dosing.

    https://pubmed.ncbi.nlm.nih.gov/16595604/

  • MRGPRX2-activating drugs (vancomycin, fluoroquinolones, neuromuscular blockers, opioids such as morphine, icatibant)

    CautionModerate

    Cortistatin is a high-potency agonist at MRGPRX2, the human mast cell pseudo-allergy receptor, and cortistatin/MRGPRX2/mast cell signaling is implicated in chronic prurigo, so combining it with other MRGPRX2 activators could additively raise the risk of flushing, urticaria, itch or anaphylactoid reactions. Additivity is inferred from shared receptor pharmacology, not observed.

    https://pubmed.ncbi.nlm.nih.gov/35283140/ ; https://pubmed.ncbi.nlm.nih.gov/34789874/

  • Insulin, sulfonylureas and other glucose-lowering agents

    CautionTheoretical

    Somatostatin-receptor agonism suppresses glucagon primarily via sstr2 and insulin primarily via sstr5 (shown for somatostatin in mouse islets), which with the marketed analogs produces unpredictable hyper- or hypoglycemia and often forces antidiabetic dose adjustment; the same is mechanistically expected of cortistatin but has never been tested in humans or, for islet hormones, with cortistatin itself.

    Somatostatin islet mechanism: https://academic.oup.com/endo/article/141/1/111/2987997 ; analog class effect from pasireotide/octreotide FDA labeling

  • Sedative-hypnotics and CNS depressants (benzodiazepines, Z-drugs, sodium oxybate, gabapentinoids, alcohol)

    CautionTheoretical

    Central cortistatin selectively deepens slow-wave sleep and reduces locomotor activity in rats, so additive sedation or next-day grogginess is plausible when layered on other CNS depressants. Rodent, intracerebroventricular dosing only — no human or peripheral-route evidence.

    https://pubmed.ncbi.nlm.nih.gov/17686045/ ; https://pubmed.ncbi.nlm.nih.gov/18374474/

  • Systemic immunosuppressants and anti-cytokine biologics (corticosteroids, anti-TNF agents, tocilizumab)

    CautionTheoretical

    Cortistatin deactivates macrophages and microglia and downregulates TNF-alpha, IL-6, IL-1beta and IFN-gamma across animal models, so combined use is immunologically additive and could increase infection susceptibility rather than simply improve disease control. Entirely inferred from animal immunomodulation data.

    https://pmc.ncbi.nlm.nih.gov/articles/PMC9489378/ ; https://pubmed.ncbi.nlm.nih.gov/18374474/

  • Opioid and non-opioid analgesics in inflammatory or neuropathic pain

    SynergisticTheoretical

    Cortistatin reduces hyperalgesia and allodynia through Gai-coupled sstr2 and ghrelin-receptor (GHSR1) spinal and peripheral actions plus suppression of neuroinflammation, mechanisms distinct from NSAID pathways, so additive analgesia is plausible. Note the nerve-injury work found partial opioid-receptor involvement of cortistatin's central effect despite no direct opioid binding, so overlap with opioids is not fully independent. Animal only.

    https://pubmed.ncbi.nlm.nih.gov/24333694/ ; https://pmc.ncbi.nlm.nih.gov/articles/PMC8309056/

  • Antiepileptic drugs

    SynergisticTheoretical

    Cortistatin is anticonvulsive against kainic-acid-induced seizures in rats and augments the neuronal h-current, suggesting a possible additive seizure-threshold effect, but no co-administration study exists and the h-current change could in principle alter excitability in either direction.

    https://pmc.ncbi.nlm.nih.gov/articles/PMC4182642/ ; https://pmc.ncbi.nlm.nih.gov/articles/PMC6740974/

Known risks(3)

  • Suppression of growth hormone secretion (shared with somatostatin)

    Moderate (acute GH suppression observed in humans; chronic harm theoretical)

    Like somatostatin, cortistatin inhibits GH secretion from the pituitary at higher doses. Chronic administration could theoretically impair GH-dependent metabolic and growth processes.

  • Potential gastrointestinal effects from somatostatin receptor activation

    Mild to Moderate (theoretical)

    Activation of somatostatin receptors can inhibit gut motility, bile secretion, and pancreatic enzyme release. Effects may be similar to somatostatin analogs like octreotide.

  • Minimal human safety data available

    Only limited human studies have been conducted (small IV infusion studies in <20 subjects). No large-scale safety or efficacy trials exist. The full human safety profile is unknown.

Drug interactions(3)

  • Somatostatin analogs (octreotide, lanreotide, pasireotide)

    Cortistatin shares all five somatostatin receptors. Co-administration could produce additive or competitive effects on GH suppression, gut motility inhibition, and insulin/glucagon regulation.

  • Ghrelin and ghrelin receptor agonists (growth hormone secretagogues)

    Cortistatin binds the ghrelin receptor (GHS-R1a) and could antagonize the appetite-stimulating and GH-releasing effects of ghrelin or synthetic secretagogues like ipamorelin and GHRP-6.

  • Anti-inflammatory agents (corticosteroids, NSAIDs)

    Cortistatin has independent anti-inflammatory activity. Combining with conventional anti-inflammatory drugs could produce additive immunosuppressive effects.

Research & benefits

Evidence base

Evidence Level
Preclinical
Total Studies
350
Human Studies
4

Cortistatin research is predominantly preclinical, with strong evidence for anti-inflammatory, sleep-promoting, cardiovascular protective, and neuroprotective effects in animal models. At least four small human studies have been conducted (Broglio et al. 2002-2004, Giordano et al. 2006), demonstrating cortistatin's endocrine effects via IV infusion in healthy volunteers and patients with acromegaly or prolactinoma. No large-scale Phase II/III therapeutic trials have been completed. The peptide's unique receptor profile (binding both somatostatin receptors and the ghrelin receptor) suggests therapeutic potential distinct from somatostatin analogs like octreotide.

Researched for(5)

Rated by confidence in the evidence

  • Enhancement of slow-wave sleep via non-somatostatin receptor mechanisms

    Low

    Deep sleep effects confirmed in rats; underlying receptor differs from somatostatin, not fully identified.

    https://pubmed.ncbi.nlm.nih.gov/17686045/ ; https://pmc.ncbi.nlm.nih.gov/articles/PMC6740974/ ; https://pubmed.ncbi.nlm.nih.gov/18374474/

  • Potent anti-inflammatory effects — suppresses TNF-alpha, IL-6, IL-12 in multiple disease models

    Low

    Reduces inflammatory markers across multiple animal disease models; no human studies exist.

    https://pmc.ncbi.nlm.nih.gov/articles/PMC9489378/ ; https://pubmed.ncbi.nlm.nih.gov/18374474/

  • Inhibition of vascular smooth muscle cell proliferation and neointimal hyperplasia

    Low

    Shown in human cells and mouse models; a single study, no human dosing trials.

    https://pubmed.ncbi.nlm.nih.gov/23595952/

  • Neuroprotective cortical activity modulation and anticonvulsant effects

    Low

    Reduces seizure activity and neuronal loss in rodent models; not yet replicated in humans.

    https://pmc.ncbi.nlm.nih.gov/articles/PMC9489378/ ; https://pmc.ncbi.nlm.nih.gov/articles/PMC4182642/ ; https://pubmed.ncbi.nlm.nih.gov/18374474/

  • Analgesic properties in rodent pain models

    Speculative

    Rodent pain relief occurs via somatostatin (sstr2) and ghrelin (GHSR1) receptors, not confirmed for MrgX2.

    https://pubmed.ncbi.nlm.nih.gov/24333694/ ; https://pmc.ncbi.nlm.nih.gov/articles/PMC8309056/ (rodent analgesia via sstr2/GHSR1)

Benefits(5)

  • Enhancement of slow-wave sleep via non-somatostatin receptor mechanisms

    de Lecea et al., Nature 1996; Spier & de Lecea, Brain Res Rev 2000

  • Potent anti-inflammatory effects — suppresses TNF-alpha, IL-6, IL-12 in multiple disease models

    Gonzalez-Rey et al., PNAS 2006; multiple preclinical inflammation studies

  • Inhibition of vascular smooth muscle cell proliferation and neointimal hyperplasia

    Duran-Prado et al., Circ Res 2013 (human aortic SMCs + carotid ligation models)

  • Neuroprotective cortical activity modulation and anticonvulsant effects

    de Lecea et al., Nature 1996; Braun et al., Brain Res 2011

  • Analgesic properties in rodent pain models

    Robas et al., J Biol Chem 2003; Morell et al., Neurobiol Dis 2014

Key studies(3)

  1. Spier AD, de Lecea L.

    Brain Research Reviews

    2000

    Comprehensive review establishing cortistatin as a distinct neuropeptide from somatostatin despite structural similarity. Describes unique cortical expression pattern, sleep-promoting effects, and distinct receptor pharmacology including binding to the ghrelin receptor.

  2. Cortistatin Inhibits Migration and Proliferation of Human Vascular Smooth Muscle Cells and Decreases Neointimal Formation on Carotid Artery Ligation

    Preclinical (cell + animal model)Human aortic SMCs + mouse carotid ligation modelsIn vitro + 4 weeks in vivo

    Duran-Prado M, Morell M, Delgado-Maroto V, et al.

    Circulation Research

    2013

    Cortistatin inhibited PDGF-stimulated proliferation and migration of human aortic smooth muscle cells via sst2/sst5 and ghrelin receptor signaling. In two carotid ligation models, cortistatin reduced neointimal formation. Cortistatin-deficient mice developed larger neointimal lesions than wild-type mice.

  3. Cortistatin mimics somatostatin by inducing a dual, dose-dependent stimulatory and inhibitory effect on growth hormone secretion

    Preclinical (in vitro, somatotrope cultures)Primary pituitary cell culturesAcute exposure studies

    Luque RM, Peinado JR, Gracia-Navarro F, et al.

    Journal of Molecular Endocrinology

    2006

    Cortistatin produced biphasic effects on GH secretion — stimulatory at low concentrations and inhibitory at high concentrations — mimicking somatostatin's dose-response pattern but with distinct receptor contributions.

Regulation & availability

Why researchers look at it

Cortistatin represents a unique intersection of sleep regulation, anti-inflammation, and cardiovascular protection — distinct from its structural cousin somatostatin. Its ability to bind both somatostatin and ghrelin receptors gives it a signaling breadth unmatched by other neuropeptides in its family.

FDA status
Not FDA-Approved. Cortistatin has no FDA-approved therapeutic indication. Limited human studies have been conducted (IV infusion in healthy volunteers and endocrine patients), but no large-scale Phase II/III therapeutic trials have been completed. No IND applications are publicly known.
WADA status
Cortistatin is not named in the 2026 Prohibited List or monitoring program. Exogenous pharmacological use falls under S0 when there is no current governmental approval for human therapeutic use, unless another prohibited category applies. Endogenous origin does not establish permission.
Prescribability
No; not FDA-approved for any indication
Availability
It is not available as a pharmaceutical product, supplement, or compounded medication. No clinical-grade formulations exist. Cortistatin-14 and cortistatin-17 are both available for research.

International status

  • EU

    Not approved

  • US

    Not FDA-approved

  • Worldwide

    No regulatory approval in any jurisdiction

Regulatory timeline(5)

  1. 1996
    Cortistatin discovered by Luis de Lecea and colleagues; published in Nature
  2. 2000
    Comprehensive characterization of cortistatin's distinct functions from somatostatin
  3. 2003
    MrgX2 identified as a high-potency cortistatin receptor that also responds to other peptide agonists
  4. 2008
    Major publications on cortistatin's anti-inflammatory role in autoimmune diseases
  5. 2013
    Cardiovascular protective effects demonstrated in vascular disease models

Sources & FAQs

Research sources(4)

Frequently asked questions(3)

How is cortistatin different from somatostatin?

Despite sharing 11 of 14 amino acids with somatostatin-14, cortistatin is a product of a separate gene on a different chromosome. It uniquely binds the ghrelin receptor (GHS-R1a) and MrgX2 receptor in addition to all somatostatin receptors. Cortistatin promotes slow-wave sleep (somatostatin does not), has stronger anti-inflammatory effects, and is predominantly expressed in cortical interneurons rather than throughout the neuroendocrine axis.

What is cortistatin's role in inflammation?

Cortistatin is one of the most potent endogenous anti-inflammatory neuropeptides. It suppresses macrophage activation, inhibits production of TNF-alpha, IL-6, and IL-12, and modulates T-helper cell balance away from inflammatory Th1 responses. In animal models, it protects against colitis, arthritis, sepsis, and atherosclerosis.

Can cortistatin help with sleep?

Preclinical research shows that cortistatin enhances slow-wave (deep) sleep when administered directly into the brain. This effect is distinct from somatostatin and appears to involve non-somatostatin receptors, possibly the MrgX2 receptor. However, no human studies have tested cortistatin for sleep and it is not available as a sleep aid.